A new trading day began on Tuesday, with Immunome Inc (NASDAQ: IMNM) stock price down -5.44% from the previous day of trading, before settling in for the closing price of $5.88. IMNM’s price has ranged from $5.35 to $21.72 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -7.10%. Meanwhile, its annual earnings per share averaged 48.00%. With a float of $75.42 million, this company’s outstanding shares have now reached $86.95 million.
Let’s determine the extent of company efficiency that accounts for 118 employees. In terms of profitability, gross margin is 89.65%, operating margin of -3382.37%, and the pretax margin is -3240.38%.
Immunome Inc (IMNM) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Immunome Inc is 13.27%, while institutional ownership is 61.45%. The most recent insider transaction that took place on Mar 25 ’25, was worth 60,684. In this transaction Director of this company bought 7,800 shares at a rate of $7.78, taking the stock ownership to the 31,415 shares. Before that another transaction happened on Mar 26 ’25, when Company’s President and CEO bought 137,100 for $7.29, making the entire transaction worth $999,459. This insider now owns 806,736 shares in total.
Immunome Inc (IMNM) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.56 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 48.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.19% during the next five years compared to -38.15% drop over the previous five years of trading.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Here are Immunome Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 53.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.18, a number that is poised to hit -0.63 in the next quarter and is forecasted to reach -2.79 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Looking closely at Immunome Inc (NASDAQ: IMNM), its last 5-days average volume was 1.07 million, which is a jump from its year-to-date volume of 1.07 million. As of the previous 9 days, the stock’s Stochastic %D was 13.00%. Additionally, its Average True Range was 0.66.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 2.15%, which indicates a significant decrease from 6.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.31% in the past 14 days, which was higher than the 80.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.95, while its 200-day Moving Average is $11.84. However, in the short run, Immunome Inc’s stock first resistance to watch stands at $6.09. Second resistance stands at $6.61. The third major resistance level sits at $6.94. If the price goes on to break the first support level at $5.24, it is likely to go to the next support level at $4.91. Now, if the price goes above the second support level, the third support stands at $4.39.
Immunome Inc (NASDAQ: IMNM) Key Stats
With a market capitalization of 483.45 million, the company has a total of 86,951K Shares Outstanding. Currently, annual sales are 9,040 K while annual income is -292,960 K. The company’s previous quarter sales were 2,740 K while its latest quarter income was -80,250 K.
